Search

Your search keyword '"Chichino, Guido"' showing total 25 results
Start Over Author "Chichino, Guido"
25 results on '"Chichino, Guido"'

1. Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units

Author

Numico, Gianmauro, Bellini, Roberta, Zanelli, Cristian, Ippoliti, Roberto, Boverio, Riccardo, Kozel, Daniela, Davio, Piero, Aiosa, Giuseppe, Bellora, Aldo, Chichino, Guido, Ruiz, Luigi, Ladetto, Marco, Polla, Biagio, Manganaro, Marco, Pistis, Gianfranco, Gemme, Carlo, Stobbione, Paolo, Desperati, Massimo, and Centini, Giacomo

Published
2020
Full Text
View/download PDF

2. Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients

Author

Bellan, Mattia, Patti, Giuseppe, Hayden, Eyal, Azzolina, Danila, Pirisi, Mario, Acquaviva, Antonio, Aimaretti, Gianluca, Aluffi Valletti, Paolo, Angilletta, Roberto, Arioli, Roberto, Avanzi, Gian Carlo, Avino, Gianluca, Balbo, Piero Emilio, Baldon, Giulia, Baorda, Francesca, Barbero, Emanuela, Baricich, Alessio, Barini, Michela, Barone-Adesi, Francesco, Battistini, Sofia, Beltrame, Michela, Bertoli, Matteo, Bertolin, Stephanie, Bertolotti, Marinella, Betti, Marta, Bobbio, Flavio, Boffano, Paolo, Boglione, Lucio, Borrè, Silvio, Brucoli, Matteo, Calzaducca, Elisa, Cammarata, Edoardo, Cantaluppi, Vincenzo, Cantello, Roberto, Capponi, Andrea, Carriero, Alessandro, Casciaro, Francesco Giuseppe, Castello, Luigi Mario, Ceruti, Federico, Chichino, Guido, Chirico, Emilio, Cisari, Carlo, Cittone, Micol Giulia, Colombo, Crizia, Comi, Cristoforo, Croce, Eleonora, Daffara, Tommaso, Danna, Pietro, Della Corte, Francesco, De Vecchi, Simona, Dianzani, Umberto, Di Benedetto, Davide, Esposto, Elia, Faggiano, Fabrizio, Falaschi, Zeno, Ferrante, Daniela, Ferrero, Alice, Gagliardi, Ileana, Gaidano, Gianluca, Galbiati, Alessandra, Gallo, Silvia, Garavelli, Pietro Luigi, Gardino, Clara Ada, Garzaro, Massimiliano, Gastaldello, Maria Luisa, Gavelli, Francesco, Gennari, Alessandra, Giacomini, Greta Maria, Giacone, Irene, Giai Via, Valentina, Giolitti, Francesca, Gironi, Laura Cristina, Gramaglia, Carla, Grisafi, Leonardo, Inserra, Ilaria, Invernizzi, Marco, Krengli, Marco, Labella, Emanuela, Landi, Irene Cecilia, Landi, Raffaella, Leone, Ilaria, Lio, Veronica, Lorenzini, Luca, Maconi, Antonio, Malerba, Mario, Manfredi, Giulia Francesca, Martelli, Maria, Marzari, Letizia, Marzullo, Paolo, Mennuni, Marco, Montabone, Claudia, Morosini, Umberto, Mussa, Marco, Nerici, Ilaria, Nuzzo, Alessandro, Olivieri, Carlo, Padelli, Samuel Alberto, Panella, Massimiliano, Parisini, Andrea, Paschè, Alessio, Pau, Alberto, Pedrinelli, Anita Rebecca, Percivale, Ilaria, Re, Roberta, Rigamonti, Cristina, Rizzi, Eleonora, Rognoni, Andrea, Roveta, Annalisa, Salamina, Luigia, Santagostino, Matteo, Saraceno, Massimo, Savoia, Paola, Sciarra, Marco, Schimmenti, Andrea, Scotti, Lorenza, Spinoni, Enrico, Smirne, Carlo, Tarantino, Vanessa, Tillio, Paolo Amedeo, Vaschetto, Rosanna, Vassia, Veronica, Zagaria, Domenico, Zavattaro, Elisa, Zeppegno, Patrizia, Zottarelli, Francesca, and Sainaghi, Pier Paolo

Published
2020
Full Text
View/download PDF

4. The WEST Study: A Retrospective and Multicentric Study on the Impact of Steroid Therapy in West Nile Encephalitis

Author

Colaneri, Marta, primary, Lissandrin, Raffaella, additional, Calia, Matteo, additional, Bassoli, Cecilia, additional, Seminari, Elena, additional, Pavesi, Alessandro, additional, Rovida, Francesca, additional, Baldanti, Fausto, additional, Muzzi, Alba, additional, Chichino, Guido, additional, Regazzetti, Angelo, additional, Grecchi, Cecilia, additional, Pan, Angelo, additional, Lupi, Matteo, additional, Franceschini, Erica, additional, Mussini, Cristina, additional, and Bruno, Raffaele, additional

Published
2023
Full Text
View/download PDF

5. Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia

Author

Carvalho Neuenschwander, Fernando, primary, Barnett-Griness, Ofra, additional, Piconi, Stefania, additional, Maor, Yasmin, additional, Sprinz, Eduardo, additional, Assy, Nimer, additional, Khmelnitskiy, Oleg, additional, Lomakin, Nikita, additional, Goloshchekin, Boris Mikhailovich, additional, Nahorecka, Ewelina, additional, Calvacante, Adilson Joaquim Westheimer, additional, Ivanova, Anastasia, additional, Zhuravel, Sergey Vladimirovich, additional, Trufanova, Galina Yurevna, additional, Bonora, Stefano, additional, Saffoury, Amer, additional, Mayo, Ami, additional, Shvarts, Yury, additional, Rizzardini, Giuliano, additional, Sobroza de Mello, Rogerio, additional, Pilau, Janaina, additional, Klinov, Alexey, additional, Valente-Acosta, Benjamin, additional, Burlaka, Oleg Olegovich, additional, Bakhtina, Natalia, additional, Bar-Meir, Maskit, additional, Shishimorov, Ivan Nikolaevich, additional, Oñate-Gutierrez, Jose, additional, Rincon, Cristian Ivan Garcia, additional, Martynenko, Tatiana Ivanovna, additional, Abrahão Hajjar, Ludhmila, additional, Procopio, Ana Carolina Nazare de Mendonca, additional, Simon, Krzystof, additional, Santiago, Walter Gabriel Chaves, additional, Fronczak, Adam, additional, Filho, Conrado Roberto Hoffmann, additional, Hussein, Osama, additional, Martynov, Vladimir Aleksandrovich, additional, Chichino, Guido, additional, Blewaska, Piotr, additional, Wroblewski, Jacek, additional, Santana, Sergio Saul Irizar, additional, Agudelo, Andres Felipe Ocampo, additional, Barczyk, Adam, additional, Gerlach, Rachael L., additional, Campbell, Eppie, additional, Bibliowicz, Aida, additional, Fathi, Reza, additional, Anderson, Patricia, additional, Raday, Gilead, additional, Klein, Michal, additional, Fehrmann, Clara, additional, Eagle, Gina, additional, Katz Ben-Yair, Vered, additional, and Levitt, Mark L., additional

Published
2022
Full Text
View/download PDF

6. Adherence to 2015 ESC Guidelines for the Treatment of Infective Endocarditis: A Retrospective Multicentre Study (LEIOT Study).

Author

Pallotto, Carlo, Bolla, Cesare, Penpa, Serena, Genga, Giovanni, Sarda, Cristina, Svizzeretto, Elisabetta, Tommasi, Andrea, Stolaj, Elisa, Salvaderi, Andrea, Piceni, Giorgia, Maconi, Antonio, Chichino, Guido, and Francisci, Daniela

Subjects
INFECTIVE endocarditis, HOSPITAL mortality, ENTEROCOCCAL infections, PATIENT compliance, RETROSPECTIVE studies, DAPTOMYCIN, RIFAMPIN
Abstract

Background: Infective endocarditis (IE) is still a severe disease with elevated morbidity and mortality. Nevertheless, the last European guidelines (GL) date back to 2015, and a recent survey described a diffuse suboptimal adherence to their recommendations. Here, we described a real-life scenario about adherence to IE treatment GL. Methods: This was a retrospective, multicentric, case–control study. All the cases of IE admitted to our wards from 2016 to 2020 were enrolled. Patients were divided into two groups, according to the non-adherence (group A, cases) or adherence (group B, controls) to 2015 ESC guidelines. Only targeted treatments were considered. Groups were compared for demographic, clinical, microbiological, and laboratory data and outcome. As a post hoc analysis, we analysed the characteristics of deviations from the guidelines and how these deviations affected mortality. Results: A total of 246 patients were enrolled, with 128 (52%) in group A and 118 (48%) in group B. Groups were homogeneous except for aetiologies: staphylococcal and blood-culture-negative IE were more frequent in group A, while streptococcal and enterococcal IE were more frequent in group B (p < 0.001). In-hospital mortality was comparable in the two groups. The most frequent causes of deviations from the guidelines were use of daptomycin, in addition to standard treatments and the missing administration of rifampin or gentamycin. Conclusions: Adherence to 2015 ESC guidelines was limited but it did not affect mortality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Response to Letter

Author

Praticò, Liliana, Mariani, Bianca, Brunetti, Enrico, Maserati, Roberta, Bruno, Antonella, Novati, Stefano, and Chichino, Guido

Published
2014
Full Text
View/download PDF

9. Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19

Author

Bellan, Mattia, primary, Azzolina, Danila, additional, Hayden, Eyal, additional, Gaidano, Gianluca, additional, Pirisi, Mario, additional, Acquaviva, Antonio, additional, Aimaretti, Gianluca, additional, Aluffi Valletti, Paolo, additional, Angilletta, Roberto, additional, Arioli, Roberto, additional, Avanzi, Gian Carlo, additional, Avino, Gianluca, additional, Balbo, Piero Emilio, additional, Baldon, Giulia, additional, Baorda, Francesca, additional, Barbero, Emanuela, additional, Baricich, Alessio, additional, Barini, Michela, additional, Barone-Adesi, Francesco, additional, Battistini, Sofia, additional, Beltrame, Michela, additional, Bertoli, Matteo, additional, Bertolin, Stephanie, additional, Bertolotti, Marinella, additional, Betti, Marta, additional, Bobbio, Flavio, additional, Boffano, Paolo, additional, Boglione, Lucio, additional, Borrè, Silvio, additional, Brucoli, Matteo, additional, Calzaducca, Elisa, additional, Cammarata, Edoardo, additional, Cantaluppi, Vincenzo, additional, Cantello, Roberto, additional, Capponi, Andrea, additional, Carriero, Alessandro, additional, Casciaro, Giuseppe Francesco, additional, Castello, Luigi Mario, additional, Ceruti, Federico, additional, Chichino, Guido, additional, Chirico, Emilio, additional, Cisari, Carlo, additional, Cittone, Micol Giulia, additional, Colombo, Crizia, additional, Comi, Cristoforo, additional, Croce, Eleonora, additional, Daffara, Tommaso, additional, Danna, Pietro, additional, Della Corte, Francesco, additional, De Vecchi, Simona, additional, Dianzani, Umberto, additional, Di Benedetto, Davide, additional, Esposto, Elia, additional, Faggiano, Fabrizio, additional, Falaschi, Zeno, additional, Ferrante, Daniela, additional, Ferrero, Alice, additional, Gagliardi, Ileana, additional, Galbiati, Alessandra, additional, Gallo, Silvia, additional, Garavelli, Pietro Luigi, additional, Gardino, Clara Ada, additional, Garzaro, Massimiliano, additional, Gastaldello, Maria Luisa, additional, Gavelli, Francesco, additional, Gennari, Alessandra, additional, Giacomini, Greta Maria, additional, Giacone, Irene, additional, Giai Via, Valentina, additional, Giolitti, Francesca, additional, Gironi, Laura Cristina, additional, Gramaglia, Carla, additional, Grisafi, Leonardo, additional, Inserra, Ilaria, additional, Invernizzi, Marco, additional, Krengli, Marco, additional, Labella, Emanuela, additional, Landi, Irene Cecilia, additional, Landi, Raffaella, additional, Leone, Ilaria, additional, Lio, Veronica, additional, Lorenzini, Luca, additional, Maconi, Antonio, additional, Malerba, Mario, additional, Manfredi, Giulia Francesca, additional, Martelli, Maria, additional, Marzari, Letizia, additional, Marzullo, Paolo, additional, Mennuni, Marco, additional, Montabone, Claudia, additional, Morosini, Umberto, additional, Mussa, Marco, additional, Nerici, Ilaria, additional, Nuzzo, Alessandro, additional, Olivieri, Carlo, additional, Padelli, Samuel Alberto, additional, Panella, Massimiliano, additional, Parisini, Andrea, additional, Paschè, Alessio, additional, Patrucco, Filippo, additional, Patti, Giuseppe, additional, Pau, Alberto, additional, Pedrinelli, Anita Rebecca, additional, Percivale, Ilaria, additional, Ragazzoni, Luca, additional, Re, Roberta, additional, Rigamonti, Cristina, additional, Rizzi, Eleonora, additional, Rognoni, Andrea, additional, Roveta, Annalisa, additional, Salamina, Luigia, additional, Santagostino, Matteo, additional, Saraceno, Massimo, additional, Savoia, Paola, additional, Sciarra, Marco, additional, Schimmenti, Andrea, additional, Scotti, Lorenza, additional, Spinoni, Enrico, additional, Smirne, Carlo, additional, Tarantino, Vanessa, additional, Tillio, Paolo Amedeo, additional, Tonello, Stelvio, additional, Vaschetto, Rosanna, additional, Vassia, Veronica, additional, Zagaria, Domenico, additional, Zavattaro, Elisa, additional, Zeppegno, Patrizia, additional, Zottarelli, Francesca, additional, and Sainaghi, Pier Paolo, additional

Published
2021
Full Text
View/download PDF

10. Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry

Author

De Rosa, Francesco Giuseppe, primary, Palazzo, Annagloria, additional, Rosso, Tiziana, additional, Shbaklo, Nour, additional, Mussa, Marco, additional, Boglione, Lucio, additional, Borgogno, Enrica, additional, Rossati, Antonella, additional, Mornese Pinna, Simone, additional, Scabini, Silvia, additional, Chichino, Guido, additional, Borrè, Silvio, additional, Del Bono, Valerio, additional, Garavelli, Pietro Luigi, additional, Barillà, Diego, additional, Cattel, Francesco, additional, Di Perri, Giovanni, additional, Ciccone, Giovannino, additional, Lupia, Tommaso, additional, and Corcione, Silvia, additional

Published
2021
Full Text
View/download PDF

11. Baseline clinical characteristics and prognostic factors in hospitalized COVID-19 patients aged ≤ 65 years: A retrospective observational study

Author

Betti, Marta, primary, Bertolotti, Marinella, additional, Ferrante, Daniela, additional, Roveta, Annalisa, additional, Pelazza, Carolina, additional, Giacchero, Fabio, additional, Penpa, Serena, additional, Massarino, Costanza, additional, Bolgeo, Tatiana, additional, Cassinari, Antonella, additional, Mussa, Marco, additional, Chichino, Guido, additional, and Maconi, Antonio, additional

Published
2021
Full Text
View/download PDF

12. Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study

Author

Longhitano, Yaroslava, primary, Racca, Fabrizio, additional, Zanza, Christian, additional, Muncinelli, Marina, additional, Guagliano, Alberto, additional, Peretti, Elisa, additional, Minerba, Anna Chiara, additional, Mari, Marta, additional, Boverio, Riccardo, additional, Salio, Mario, additional, Chichino, Guido, additional, Franceschi, Francesco, additional, Piccioni, Andrea, additional, Abenavoli, Ludovico, additional, Salvini, Mauro, additional, and Artico, Marco, additional

Published
2020
Full Text
View/download PDF

13. Baseline Clinical Characteristics and Prognostic Factors in Hospitalized COVID-19 Patients Aged ≤ 65 Years: A Retrospective Observational Study

Author

Betti, Marta, primary, Bertolotti, Marinella, additional, Ferrante, Daniela, additional, Roveta, Annalisa, additional, Pelazza, Carolina, additional, Giacchero, Fabio, additional, Penpa, Serena, additional, Massarino, Costanza, additional, Bolgeo, Tatiana, additional, Cassinari, Antonella, additional, Mussa, Marco, additional, Chichino, Guido, additional, and Maconi, Antonio, additional

Published
2020
Full Text
View/download PDF

18. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy

Author

Serena, Merante, Merante, Serena, Guido, Chichino, Chichino, Guido, Emanuela, Boveri, Boveri, Emanuela, Enrico, Gottardi, Gottardi, Enrico, Simona, Soverini, Soverini, Simona, Daniela, Cilloni, Cilloni, Daniela, Giovanni, Martinelli, and Martinelli, Giovanni

Subjects
Adult, Male, Acquired Immunodeficiency Syndrome, Reverse Transcriptase Polymerase Chain Reaction, Antineoplastic Agents, Protein-Tyrosine Kinases, Piperazines, Receptor, Platelet-Derived Growth Factor beta, Proto-Oncogene Proteins c-kit, Pyrimidines, Mastocytosis, Systemic, Benzamides, Eosinophilia, Imatinib Mesylate, Humans, Polymorphism, Restriction Fragment Length, Monomeric GTP-Binding Proteins
Published
2006

19. First Case of an AIDS Patient With Systemic Mast Cell Disease Associated With Eosinophilia FIP1-Positive Treated With Imatinib Mesylate Therapy

Author

Chichino Guido, Cilloni Daniela, Martinelli Giovanni, Gottardi Enrico, Merante Serena, Soverini Simona, Boveri Emanuela, Merante S, Chichino G, Boveri E, Gottardi E, Soverini S, Cilloni D, and Martinelli G

Subjects
Cancer Research, EOSINOPHILIA, business.industry, IMATINIB MESYLATE, Disease, medicine.disease, Mast cell, Imatinib mesylate, medicine.anatomical_structure, Oncology, Acquired immunodeficiency syndrome (AIDS), Immunology, medicine, Eosinophilia, medicine.symptom, business
Abstract

No abstract available

Published
2006

21. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy

Author

Mounier, Nicolas, Spina, Michele, Gabarre, Jean, Raphael, Martine, Rizzardini, Giuliano, Golfier, Jean-Baptiste, Vaccher, Emanuela, Carbone, Antonino, Coiffier, Bertrand, Chichino, Guido, Bosly, Andre, Tirelli, Umberto, and Gisselbrecht, Christian

Abstract

We aimed to compare AIDS risk–adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART). A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4+cell counts below 0.10 × 109/L (100/mm3). A total of 218 good-risk patients (HIV score 0) received ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone) or CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone); 177 intermediate-risk patients (HIV score 1), CHOP or low-dose CHOP (Ld-CHOP); and 90 poor-risk patients (HIV score 2-3), Ld-CHOP or VS (vincristine and steroid). The 5-year overall survival (OS) in the good-risk group was 51% for ACVBP versus 47% for CHOP (P= .85); in the intermediate-risk group, 28% for CHOP versus 24% for Ld-CHOP (P= .19); and in the poor-risk group, 11% for Ld-CHOP versus 3% for VS (P= .14). The time-dependent Cox model demonstrated that the only significant factors for OS were HAART (relative risk [RR] 1.6, P< .001), HIV score (RR 1.7, P< .001), and the International Prognostic Index (IPI) score (RR 1.5, P< .001) but not chemotherapy regimen. Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy.

Published
2006
Full Text
View/download PDF

23. Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO 2 Requirements.

Author

Neuenschwander FC, Barnett-Griness O, Piconi S, Maor Y, Sprinz E, Assy N, Khmelnitskiy O, Lomakin NV, Goloshchekin BM, Nahorecka E, Joaquim Westheimer Calvacante A, Ivanova A, Vladimirovich Zhuravel S, Yurevna Trufanova G, Bonora S, Saffoury A, Mayo A, Shvarts YG, Rizzardini G, Sobroza de Mello R, Pilau J, Klinov A, Valente-Acosta B, Olegovich Burlaka O, Bakhtina N, Bar-Meir M, Nikolaevich Shishimorov I, Oñate-Gutierrez J, García Rincón CI, Ivanovna Martynenko T, Hajjar LA, Carolina Nazare de Mendonca Procopio A, Simon K, Gabriel Chaves Santiago W, Fronczak A, Roberto Hoffmann Filho C, Hussein O, Aleksandrovich Martynov V, Chichino G, Blewaska P, Wroblewski J, Saul Irizar Santana S, Felipe Ocampo Agudelo A, Barczyk A, Lask Gerlach R, Campbell E, Bibliowicz A, Fathi R, Anderson P, Raday G, Klein M, Fehrmann C, Eagle G, Ben-Yair VK, and Levitt ML

Abstract

Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral treatment under investigation being evaluated for treatment of hospitalized patients with severe COVID-19 pneumonia. A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted in 57 sites worldwide from August 2020 to July 2021. Patients received either opaganib (n = 230; 500 mg twice daily) or matching placebo (n = 233) for 14 days. The primary outcome was the proportion of patients no longer requiring supplemental oxygen by day 14. Secondary outcomes included changes in the World Health Organization Ordinal Scale for Clinical Improvement, viral clearance, intubation, and mortality at 28 and 42 days. Pre-specified primary and secondary outcome analyses did not demonstrate statistically significant benefit (except nominally for time to viral clearance). Post-hoc analysis revealed the fraction of inspired oxygen (FIO 2 ) at baseline was prognostic for opaganib treatment responsiveness and corresponded to disease severity markers. Patients with FIO 2 levels at or below the median value (≤60%) had better outcomes after opaganib treatment (n = 117) compared to placebo (n = 134). The proportion of patients with ≤60% FIO 2 at baseline that no longer required supplemental oxygen (≥24 h) by day 14 of opaganib treatment increased (76.9% vs. 63.4%; nominal p -value = 0.033). There was a 62.6% reduction in intubation/mechanical ventilation (6.84% vs. 17.91%; nominal p -value = 0.012) and a clinically meaningful 62% reduction in mortality (5.98% vs. 16.7%; nominal p -value = 0.019) by day 42. No new safety concerns were observed. While the primary analyses were not statistically significant, post-hoc analysis suggests opaganib benefit for patients with severe COVID-19 requiring supplemental oxygen with an FIO 2 of ≤60%. Further studies are warranted to prospectively confirm opaganib benefit in this subpopulation.

Published
2024
Full Text
View/download PDF

24. Imported hantavirus cardiopulmonary syndrome in an Italian traveller returning from Cuba.

Author

Rovida F, Percivalle E, Sarasini A, Chichino G, and Baldanti F

Subjects
Antibodies, Viral blood, Cuba epidemiology, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, Orthohantavirus immunology, Hantavirus Pulmonary Syndrome blood, Hantavirus Pulmonary Syndrome diagnosis, Humans, Italy ethnology, Male, Middle Aged, Real-Time Polymerase Chain Reaction, Orthohantavirus isolation & purification, Hantavirus Pulmonary Syndrome virology, Travel
Abstract

Hantavirus hemorrhagic fever with renal syndrome is endemic in Europe and Asia, while hantavirus cardiopulmonary syndrome (HCPS) is endemic in Northern, Central and Southern America. The first case of imported HCPS involving an Italian traveller returning from Cuba is reported.

Published
2013

25. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.

Author

Merante S, Chichino G, Boveri E, Gottardi E, Soverini S, Cilloni D, and Martinelli G

Subjects
Acquired Immunodeficiency Syndrome metabolism, Adult, Antineoplastic Agents therapeutic use, Benzamides, Eosinophilia metabolism, Humans, Imatinib Mesylate, Male, Mastocytosis, Systemic metabolism, Polymorphism, Restriction Fragment Length, Proto-Oncogene Proteins c-kit genetics, Receptor, Platelet-Derived Growth Factor beta analysis, Reverse Transcriptase Polymerase Chain Reaction, Acquired Immunodeficiency Syndrome complications, Eosinophilia complications, Mastocytosis, Systemic diagnosis, Monomeric GTP-Binding Proteins analysis, Piperazines therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, Pyrimidines therapeutic use
Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results